Artwork

Content provided by The Motley Fool. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Motley Fool or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Wildcard: BICO, Bioprinting, and Bioconvergence

26:03
 
Share
 

Manage episode 314744844 series 46582
Content provided by The Motley Fool. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Motley Fool or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

We get back to Wednesday's healthcare roots with a rundown on BICO Group, a Sweden-based business that enables researchers and scientists to model, build, test, analyze and observe 3-D printed cells, tissues and organs.

This company helps researchers reduce the time and cost of identifying potentially efficacious drugs and can help provide initial results on whether drug compounds are safe and effective before having to test them on animals or humans.

We talk through the huge implications it could have for research in life sciences and personalized medicine and try to clear up some of the jargon around the company.

Stocks: (OM:BICO)

Check out more of our content here:

Podcasts

Youtube

Twitter

Reach us by Email @ IndustryFocus@fool.com

  continue reading

2042 episodes

Artwork
iconShare
 
Manage episode 314744844 series 46582
Content provided by The Motley Fool. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Motley Fool or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

We get back to Wednesday's healthcare roots with a rundown on BICO Group, a Sweden-based business that enables researchers and scientists to model, build, test, analyze and observe 3-D printed cells, tissues and organs.

This company helps researchers reduce the time and cost of identifying potentially efficacious drugs and can help provide initial results on whether drug compounds are safe and effective before having to test them on animals or humans.

We talk through the huge implications it could have for research in life sciences and personalized medicine and try to clear up some of the jargon around the company.

Stocks: (OM:BICO)

Check out more of our content here:

Podcasts

Youtube

Twitter

Reach us by Email @ IndustryFocus@fool.com

  continue reading

2042 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide